Royalty Pharma EVP Marshall Urist sells $235,594 in shares

Marshall Urist, Executive Vice President of Research & Investments at Royalty Pharma plc (NASDAQ:RPRX), sold Class A Ordinary Shares totaling $235,594 on October 5, 2026.

Mr. Urist disposed of 4,126 Class A Ordinary Shares at a price of $57.1 per share. The transaction was executed under a Rule 10b5-1 trading plan, which was adopted by Mr. Urist on June 26, 2026.The sale comes as Royalty Pharma shares have delivered a strong 61% return over the past year, currently trading at $56.93 with a market capitalization of $32.7 billion. According to InvestingPro analysis, the stock appears overvalued relative to its Fair Value estimate, placing it among stocks on the Most Overvalued list. For deeper insights, investors can access a comprehensive Pro Research Report on RPRX, one of 1,400+ reports available on the platform.

Following this transaction, Mr. Urist directly holds no Class A Ordinary Shares. He continues to indirectly hold 19,020 Class A Ordinary Shares through an IRA.

In addition to the reported Class A Ordinary Shares, Mr. Urist and family vehicles he controls hold limited partnership interests in RPI US Partners 2019, LP, which are exchangeable into 2,444,120 Class A Ordinary Shares. He also holds Class E Ordinary Shares of Royalty Pharma Holdings Ltd ("RPH"), exchangeable into 1,356,528 Class A Ordinary Shares, which are subject to vesting conditions.

In other recent news, Royalty Pharma reported robust second-quarter results for 2026, with portfolio receipts increasing by 6% to $773 million, and total receipts rising by 14%, surpassing management’s expectations. Following these strong results, the company raised its full-year outlook for the second consecutive quarter, indicating continued confidence in its financial performance. Analysts have taken note, with BofA Securities raising its price target on Royalty Pharma stock to $63.00 from $62.00, maintaining a Buy rating due to the strength seen in products like Tremfya, Voranigo, Imdelltra, and Evrysdi.

Meanwhile, TD Cowen also adjusted its price target for Royalty Pharma shares, increasing it to $68 from $65, while keeping a Buy rating. This change comes despite the removal of pelacarsen and olpasiran royalties from their model, following the Phase III HORIZON trial failure of pelacarsen. The trial’s outcome suggested that Lp(a) might not be an independent modifiable risk factor for heart disease, affecting previous revenue estimates. These developments are part of a broader trend in the biotech sector, where funding has risen by 75% year-over-year, driven by increased initial public offerings and venture funding.